Home > Oncology > BCC 2019 > St. Gallen Consensus > DCIS: de-escalation of (adjuvant) therapy

DCIS: de-escalation of (adjuvant) therapy

Conference
BCC 2019

De-escalation of therapy for patients with ductal carcinoma in situ (DCIS) was surveyed in 4 questions. Almost all panellists (98%) agreed that screening-detected, small DCIS with favourable biological features (e.g. G1-2, or other low risk features) has a better prognosis and therefore may require less intensive treatment. In line with this, 84% of the panellists found it a reasonable option to omit radiotherapy for patients with DCIS with favourable features and a clear tumour-free surgical margin (≥ 5 mm). Only a small majority of the panellists (56%) found it a reasonable option to omit endocrine therapy in these patients, while 66% of the panellists found it a reasonable option to omit both radiotherapy and endocrine therapy.



Posted on